A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease
patients who are not concomitantly treated with L-dopa will be investigated with a doses.